Literature DB >> 10807877

Two distinct congenital arrhythmias evoked by a multidysfunctional Na(+) channel.

M W Veldkamp1, P C Viswanathan, C Bezzina, A Baartscheer, A A Wilde, J R Balser.   

Abstract

The congenital long-QT syndrome (LQT3) and the Brugada syndrome are distinct, life-threatening rhythm disorders linked to autosomal dominant mutations in SCN5A, the gene encoding the human cardiac Na(+) channel. It is believed that these two syndromes result from opposite molecular effects: LQT3 mutations induce a gain of function, whereas Brugada syndrome mutations reduce Na(+) channel function. Paradoxically, an inherited C-terminal SCN5A mutation causes affected individuals to manifest electrocardiographic features of both syndromes: QT-interval prolongation (LQT3) at slow heart rates and distinctive ST-segment elevations (Brugada syndrome) with exercise. In the present study, we show that the insertion of the amino acid 1795insD has opposite effects on two distinct kinetic components of Na(+) channel gating (fast and slow inactivation) that render unique, simultaneous effects on cardiac excitability. The mutation disrupts fast inactivation, causing sustained Na(+) current throughout the action potential plateau and prolonging cardiac repolarization at slow heart rates. At the same time, 1795insD augments slow inactivation, delaying recovery of Na(+) channel availability between stimuli and reducing the Na(+) current at rapid heart rates. Our findings reveal a novel molecular mechanism for the Brugada syndrome and identify a new dual mechanism whereby single SCN5A mutations may evoke multiple cardiac arrhythmia syndromes by influencing diverse components of Na(+) channel gating function. The full text of this article is available at http://www.circresaha.org.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807877     DOI: 10.1161/01.res.86.9.e91

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  97 in total

1.  Role of the C-terminal domain in inactivation of brain and cardiac sodium channels.

Authors:  M Mantegazza; F H Yu; W A Catterall; T Scheuer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-11       Impact factor: 11.205

2.  Na(+) channel mutation that causes both Brugada and long-QT syndrome phenotypes: a simulation study of mechanism.

Authors:  Colleen E Clancy; Yoram Rudy
Journal:  Circulation       Date:  2002-03-12       Impact factor: 29.690

Review 3.  CaMKII in myocardial hypertrophy and heart failure.

Authors:  Mark E Anderson; Joan Heller Brown; Donald M Bers
Journal:  J Mol Cell Cardiol       Date:  2011-01-27       Impact factor: 5.000

Review 4.  Defective cardiac ion channels: from mutations to clinical syndromes.

Authors:  Colleen E Clancy; Robert S Kass
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

5.  Quantitative modelling of interaction of propafenone with sodium channels in cardiac cells.

Authors:  M Pásek; J Simurda
Journal:  Med Biol Eng Comput       Date:  2004-03       Impact factor: 2.602

6.  Structural effects of an LQT-3 mutation on heart Na+ channel gating.

Authors:  M Tateyama; H Liu; A-S Yang; J W Cormier; R S Kass
Journal:  Biophys J       Date:  2004-03       Impact factor: 4.033

7.  Functional Interactions between Distinct Sodium Channel Cytoplasmic Domains through the Action of Calmodulin.

Authors:  Franck Potet; Benjamin Chagot; Mircea Anghelescu; Prakash C Viswanathan; Svetlana Z Stepanovic; Sabina Kupershmidt; Walter J Chazin; Jeffrey R Balser
Journal:  J Biol Chem       Date:  2009-01-26       Impact factor: 5.157

Review 8.  Brugada syndrome: current clinical aspects and risk stratification.

Authors:  Takanori Ikeda
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-07       Impact factor: 1.468

9.  Na(+) channel I-II loop mediates parallel genetic and phosphorylation-dependent gating changes.

Authors:  Donald M Bers; Anthony W Herren
Journal:  Circulation       Date:  2012-10-23       Impact factor: 29.690

10.  Long QT syndrome: from channels to cardiac arrhythmias.

Authors:  Arthur J Moss; Robert S Kass
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.